Published in Nat Immunol on October 07, 2002
Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies | NCT00114647
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Memory CD8 T-cell differentiation during viral infection. J Virol (2004) 6.75
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A (2004) 4.56
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A (2005) 4.02
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol (2007) 3.85
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol (2012) 3.81
A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity (2009) 3.66
Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med (2010) 3.32
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest (2005) 3.08
Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med (2007) 3.05
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood (2006) 2.95
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med (2006) 2.70
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol (2011) 2.54
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol (2005) 2.48
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood (2008) 2.30
Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol (2007) 2.21
Limited durability of viral control following treated acute HIV infection. PLoS Med (2004) 2.16
Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. Vaccine (2009) 2.12
Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol (2006) 2.09
Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol (2004) 2.07
Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol (2005) 2.06
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood (2006) 1.94
Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol (2008) 1.94
HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med (2008) 1.91
Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol (2007) 1.90
A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med (2007) 1.88
Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood (2011) 1.85
Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol (2009) 1.84
Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol (2008) 1.82
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol (2009) 1.80
Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol (2008) 1.79
Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med (2004) 1.79
Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication. J Virol (2007) 1.78
Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr (2009) 1.78
Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology (2007) 1.77
A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis (2008) 1.76
A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest (2011) 1.75
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol (2013) 1.74
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest (2011) 1.71
Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest (2003) 1.69
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol (2011) 1.66
Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med (2011) 1.66
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS (2011) 1.63
Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol (2009) 1.62
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis (2012) 1.61
Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol (2010) 1.60
Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther (2009) 1.59
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One (2007) 1.52
CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS One (2007) 1.52
Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc Natl Acad Sci U S A (2007) 1.51
Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol (2006) 1.45
Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev (2011) 1.44
Rapid up-regulation and granule-independent transport of perforin to the immunological synapse define a novel mechanism of antigen-specific CD8+ T cell cytotoxic activity. J Immunol (2009) 1.42
Characterization of CD8+ T cell differentiation following SIVΔnef vaccination by transcription factor expression profiling. PLoS Pathog (2015) 1.42
Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving. Proc Natl Acad Sci U S A (2012) 1.41
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis (2008) 1.39
Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS (2009) 1.39
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis (2013) 1.36
Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol (2012) 1.32
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol (2003) 4.48
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol (2003) 3.29
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA (2010) 3.14
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis (2002) 2.57
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science (2013) 2.48
Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity (2012) 2.41
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis (2011) 2.40
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol (2004) 2.01
Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis (2003) 1.97
The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 1.94
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86
Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol (2009) 1.84
IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood (2004) 1.82
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78
Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog (2011) 1.77
High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med (2002) 1.74
Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood (2002) 1.73
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res (2011) 1.64
CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res Hum Retroviruses (2007) 1.64
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS (2011) 1.63
Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proc Natl Acad Sci U S A (2008) 1.62
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis (2001) 1.54
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 1.53
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Thymic output: a bad TREC record. Nat Immunol (2003) 1.50
Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J Virol (2010) 1.47
Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors. Clin Immunol (2012) 1.47
Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS One (2007) 1.45
Demographic, clinical, and virologic characteristics of African-born persons with HIV/AIDS in a Minnesota hospital. AIDS Patient Care STDS (2007) 1.45
Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol (2003) 1.44